Unlearn.AI

CNS Summit 2024 is just days away, and this year’s theme, “Driving the Future of Life Sciences,” closely aligns with our mission at Unlearn. As the only company advancing #AI models sophisticated enough to create #digitaltwins of individual study participants, we enable biotech and pharma companies to accelerate trials, improve reliability, and meet today’s rigorous standards in #clinicaldevelopment through our powerful tool—the Unlearn Platform. Discover how we’re reshaping the future of #clinicaltrials in CEO Steven Herne’s latest blog post. 🚀

Huntington’s disease has one of the highest #clinicaltrial failure rates, but our AI-generated #digitaltwins of trial participants are revolutionizing clinical development by providing faster and more cost-effective solutions. 📲 Connect with us at #HSG2024 tomorrow and discover how our proven solutions are accelerating the delivery of life-saving treatments to patients. To learn more about our Huntington’s Digital Twin Generator, visit: https://bit.ly/3Cf4WwT

Unlearn Team at #CTAD24! 🚀 A huge thank you to everyone who connected with us to explore how the Unlearn Platform’s suite of clinical trial solutions can streamline clinical development. If you missed us at the event, reach out to us here: https://lnkd.in/gMPUV66F ——— CTAD Clinical Trials on Alzheimer's Disease; Luis Olmos, PhD, MBA; Tricia Sorrentino; Alyssa Vanderbeek

Biocom California’s CEO Summit is just around the corner! Join us on November 7 at 1:15 PM PT as our founder and VP of Technology, Jonathan Walsh, takes the stage for the session, “Unlocking the Future of Drug Development: The Power of AI” 💊 Don’t miss out! https://bit.ly/3S6i0KR ——— #BiocomCEOSummit

This Alzheimer’s Awareness Month, we’re shining light on the pressing need for innovative solutions for Alzheimer’s #clinicaltrials. With alarmingly low success rates, we’re tackling this challenge head-on with Unlearn Platform. By leveraging AI-generated #digitaltwins of trial participants, we offer a comprehensive suite of clinical trial solutions designed to streamline development and improve the likelihood of successful outcomes. 🚀 Read our case study to learn how we're advancing Alzheimer’s research and accelerating the path to effective treatments: https://bit.ly/4hjNWW9 ——— Alzheimer's Foundation of America

We’re excited to be back at #CNSSummit2024, showcasing the Unlearn Platform—an AI-powered breakthrough in clinical trial solutions. Last year, we took the main stage with our founder, Charles Fisher, QurAlis CEO and Co-Founder Kasper Roet, and moderator Junaid Bajwa from Microsoft Health Futures for a powerful session on “Is the AI Revolution in Clinical Trials Here?” This year, we’re here to prove that it is. 🚀

The Huntington Study Group reports that between 4 and 5 out of every 100,000 people in the U.S. are living with Huntington’s disease. If you’re attending #HSG2024 next week, connect with our team to discover how AI-generated #digitaltwins of trial participants can streamline your Huntington’s clinical development with faster, more cost-effective solutions. 🚀 https://bit.ly/3UsBBFi —— Andrew Stelzer; Anurag Kulkarni

#UnlearnerSpotlight 🚀 Greg Connor Role: “As the Director of Proposals, I sit within the Commercial team but have the unique opportunity to collaborate with all our internal teams to gather the critical information our clients need when choosing to partner with Unlearn. My mission is to showcase the value of our innovative technology to clients—and ultimately their patients—in a way that inspires confidence in a lasting partnership with Unlearn.” Favorite part about working at Unlearn: “What I enjoy most about being at Unlearn is working alongside brilliant, inspiring people every day. Collaborating across various teams and seeing the innovative ways we're using AI technology to tackle complex medical challenges energizes me for what we’ll achieve next.”

#CTAD24 is tomorrow! Don’t miss the opportunity to connect with our team and discover how we can streamline your Alzheimer’s clinical trial. 🚀 Learn more in our case study: https://lnkd.in/gE2UfyMt

Supporting #ALS research is close to our hearts at Unlearn, and this week gave us two wonderful chances to both raise awareness and showcase the impact of our work. On Wednesday, we took part in the 10th anniversary of The ALS Association Ice Bucket Challenge. Our co-founder Jonathan Walsh, along with Tricia Sorrentino, Luis Olmos, PhD, MBA, and Anurag Kulkarni, braved the cold for #IceBucket10 —helping raise awareness for ALS research. It’s amazing how much this movement has done over the past decade, and we’re proud to keep the momentum going! On Thursday, we were also at the 23rd Annual Northeast ALS Consortium (NEALS) Meeting, where our very own Rachel Mak-McCully gave a talk on how AI-generated #digitaltwins can boost the statistical power of ALS #clinicaltrials, enabling more confident decision-making about treatment efficacy. NEALS is a leading conference that brings together researchers, clinicians, and advocates, and it’s exciting to see how the community is pushing the boundaries of ALS research. We’re honored to be part of the conversation about how #AI can make a real difference in the fight against ALS. On that note, last month we announced our partnership with ProJenX applying our digital twins technology to PRO-101, its Phase 1 clinical trial of prosetin. We're excited about this opportunity to accelerate their research and move closer to new treatments for those affected by ALS. Our commitment remains strong—whether it's raising awareness, advancing trials with AI, or collaborating with partners, we're dedicated to making a meaningful impact in the fight against this disease.